Authors

    Language

    English

    Publication Date

    1-1-2023

    Journal

    The Journal of Cancer

    DOI

    10.1097/PPO.0000000000000637

    PMID

    36693154

    PMCID

    PMC9881841

    PubMedCentral® Posted Date

    1-1-2024

    PubMedCentral® Full Text Version

    Post-print

    Abstract

    Cellular immunotherapy of cancer in the form of chimeric antigen receptor-modified T-cell therapy has become a standard treatment for lymphoid and more recently plasma cell malignancies. Although their successes in these cancers represent a breakthrough for adoptive cell therapy, there are several challenges to their continued growth in the field of cancer medicine. In this review, we discuss the progress made thus far toward achieving "off-the-shelf" accessibility of cell therapies that has the potential to greatly offset the costs associated with the current practice of making patient-specific products. We also review the innovations under investigation that attempt to make cellular therapy applicable to solid tumors as well.

    Keywords

    Humans, T-Lymphocytes, Neoplasms, Immunotherapy, Adoptive, Immunotherapy, Cell- and Tissue-Based Therapy, Cellular Immunotherapy, Chimeric antigen receptor (CAR)- T cell therapy, lymphoid malignancies, multiple myeloma, adoptive cell therapy, off-the-shelf cell therapy

    Published Open-Access

    yes

    Share

    COinS
     
     

    To view the content in your browser, please download Adobe Reader or, alternately,
    you may Download the file to your hard drive.

    NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.